ScreenerHero

ONCY Oncolytics Biotech Inc.

NAS · US · Healthcare · Biotechnology · oncolyticsbiotech.com
0.5958USD-0.37%Mkt Cap: 75.97M $P/E: —

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunot…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap75.97M USD
Enterprise Value72.58M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-28.76M USD
Revenue/Share—
Last Price0.5958 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees29
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.05
PEG—
EV/EBITDA-1.93
EV/Revenue—
P/S—
P/B-12.20
EPS (TTM)-0.35
EPS (Forward)-0.20
52W Range
0.57572% of range1.510
52W High1.510 USD
52W Low0.5757 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE757.02%
ROA-379.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.11M USD
CapEx (TTM)6.00K USD
FCF Margin—
FCF Yield-15.81%
Net Debt-3.67M USD
Net Debt/EBITDA0.10
Balance Sheet
Debt/Equity-0.15
Current Ratio1.35
Quick Ratio1.02
Book Value/Sh-0.05 USD
Cash/Share0.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateMay 25, 2018
Splits
Last Split10:95
Split DateMay 25, 2018
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.151 USD
Upside (mean)+596.7%
Target Range2.850 USD – 5.862 USD
2.850+596.7% to mean5.862
# Analysts6
Ownership
Shares Out.127.51M
Float125.05M
Insiders2.05%
Institutions3.30%
Short Interest
Short Ratio9.7d
Short % Float6.91%
Short % Out.6.78%
Shares Short8.65M
Short (prev mo.)8.46M
Technical
SMA 500.7796 (-23.6%)
SMA 2000.9074 (-34.3%)
Beta1.16
S&P 52W Chg15.78%
Avg Vol (30d)1.01M
Avg Vol (10d)1.20M
Technical Indicators
RSI (14)26.0
MACD-0.0557
MACD Signal-0.0451
MACD Hist.-0.0106
BB Upper0.8616 USD
BB Middle0.7067 USD
BB Lower0.5518 USD
BB Width43.84%
ATR (14)0.0431 USD
Vol Ratio (20d)0.57x